The Company is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company's product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets. The Company was established on February 26, 2010. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on July 18, 2018.
Headquarters
1014, 17, Daehak4-Ro, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do
Suwon; Gyeonggi;
Contact Details: Purchase the Olix Pharmaceuticals, Inc. report to view the information.
Website: http://www.olixpharma.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service